CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

With Canada set to drastically increase its defence spend in 2026, Calian is expected to see a major boon of new contracts.

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

Desjardins analyst Brent Sadler published his year-ahead report for domestic power and utilities stocks, ...

Given these factors, my favorite index ETF to outperform in 2026 is the Vanguard Mega Cap Growth ETF as it's one of the most ...